Table 3.
AEs in ≥20% of all patients of any grade and all patients of grade ≥3: mITT population.
| AEs by Preferred Term | Number of patients (N = 10) | ||
|---|---|---|---|
| Any grade | Grade 3 | Grade 4 | |
| Leukopenia/white blood cell count decreased | 10 | 0 | 10 |
| Lymphopenia/lymphocyte count decreased | 10 | 0 | 10 |
| Neutropenia/neutrophil count decreased | 10 | 0 | 10 |
| Anemia/red blood cell count decreased | 9 | 9 | 0 |
| Thrombocytopenia/platelet count decreased | 6 | 1 | 4 |
| Hyponatremia | 6 | 5 | 0 |
| Hypophosphatemia | 4 | 1 | 1 |
| Fatigue | 7 | 2 | 0 |
| Tumor pain | 3 | 2 | 0 |
| Rash | 5 | 0 | 1 |
| Pyrexia | 6 | 1 | 0 |
| Decreased appetite | 5 | 1 | 0 |
| Constipation | 4 | 1 | 0 |
| Hypotension | 4 | 1 | 0 |
| Hypocalcemia | 3 | 1 | 0 |
| Abdominal pain | 2 | 1 | 0 |
| Acute kidney injury | 2 | 1 | 0 |
| CRS | 2 | 1 | 0 |
| Dyspnea | 2 | 1 | 0 |
AE, adverse event; CRS, cytokine release syndrome; mITT, modified intent-to-treat.